Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cortisone acetate
Drug ID BADD_D00533
Description Cortisone acetate was first isolate in 1935 and became more widely researched in 1949.[A226295] Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, and gastrointestinal diseases and disorders.[A226300,L13203] Cortisone acetate was granted FDA approval on 13 June 1950.[L15107]
Indications and Usage For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders.
Marketing Status Prescription; Discontinued
ATC Code H02AB10; S01BA03
DrugBank ID DB01380
KEGG ID D00973
MeSH ID D003348
PubChem ID 5745
TTD Drug ID D0X4RS
NDC Product Code 0220-1554; 0143-1202; 0220-1553; 0143-9700; 64958-0025; 49452-2321; 0220-1550
Synonyms Cortisone | Cortisone Acetate | 17-Hydroxy-3,11,20-trioxopregn-4-en-21-yl acetate | Cortone Acetate | Adreson
Chemical Information
Molecular Formula C23H30O6
CAS Registry Number 50-04-4
SMILES CC(=O)OCC(=O)C1(CCC2C1(CC(=O)C3C2CCC4=CC(=O)CCC34C)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alkalosis hypokalaemic14.01.02.002--Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Asthenia08.01.01.0010.010733%Not Available
Benign intracranial hypertension17.07.02.001--Not Available
Blood cortisol decreased13.10.09.0040.010733%Not Available
Carbohydrate tolerance decreased13.02.02.003--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cataract subcapsular06.06.01.002--Not Available
Confusional state19.13.01.001; 17.02.03.0050.010733%
Cough22.02.03.0010.010733%
Crohn's disease07.08.01.015; 10.02.01.0050.016100%Not Available
Depression19.15.01.0010.010733%
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Diabetes mellitus05.06.01.001; 14.06.01.001--Not Available
Diarrhoea07.02.01.0010.016100%
Drug hypersensitivity10.01.01.0010.096597%Not Available
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Erythema23.03.06.0010.010733%Not Available
Euphoric mood19.04.02.0060.010733%
Exophthalmos06.09.04.001; 05.02.02.002--Not Available
Fluid retention14.05.06.002; 20.01.02.003--Not Available
Gait disturbance17.02.05.016; 08.01.02.0020.010733%
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.002800%Not Available
Haemoglobin decreased13.01.05.0030.010733%Not Available
Hallucination19.10.02.0020.016100%
Hallucination, auditory19.10.02.0030.010733%Not Available
Headache17.14.01.001--
Hirsutism23.02.04.001; 05.05.01.005--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypertension24.08.02.0010.010733%
The 1th Page    1 2 3    Next   Last    Total 3 Pages